title: Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
abstract: BACKGROUND
  The role of germline mutations in BRCA1 and BRCA2 genes in the risk of the development of ovarian cancer is clinically well established. BRCA1/2 testing seems to have increasing role in clinical management in patients with advanced ovarian cancer who require treatment with poly(ADP-ribose) polymerase inhibitors.
  
  
  METHODS
  Between 2002 - 2008, 125 consecutive patients with ovarian cancer were categorized as having three founder mutations in the BRCA1 gene in Poland as: 5382insC [exon 20], 4153delA [exon 11.17], and 300 T > G [exon 5]. PFS (progression free survival) and OS (overall survival) were determined by Kaplan-Meier analysis with log rank test, univariate comparisons, and multivariate regression analysis using Cox proportional hazards model.
  
  
  RESULTS
  Of the 125 patients, the founder mutations of BRCA1 were reported in 17 patients (13.6 %). The median OS was longer for BRCA mutated patients (not reached vs 35.6 months, p = 0.041). PFS was similar for both kinds of ovarian cancer. In multivariate analysis, age ≥70 years, suboptimal surgery, and BRCA1 wild type were poor prognostic factors. The BRCA1 mutation reduced the likelihood of death in ovarian cancer by 86 % (HR 0.14; CI: 0.032-0.650, p = 0.012).
  
  
  CONCLUSIONS
  In conclusion, we found better overall survival for ovarian cancer patients with BRCA1 germline mutations in comparison with patients without these mutations (sporadic) ovarian cancer. Thus, BRCA1 germline mutations appear to be an independent prognostic factor for ovarian cancer.
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Agnieszka
authors.identifier: 0000-0001-8318-0892
authors.initials: A
authors.lastname: Synowiec
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Wcisło
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Lubomir
authors.initials: L
authors.lastname: Bodnar
authors.affiliation: Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Bohdan
authors.initials: B
authors.lastname: Górski
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Szenajch
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szarlej-Wcisło
authors.affiliation: Department of Oncology, Military Institute of Medicine, 128 Szaserow Str., 04-141 Warsaw, Poland.
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik
keywords: Chemotherapy; Germline mutations of BRCA1; Ovarian cancer; Survival